[144] Crinetics Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. (CRNX) submitted a Form 144 notice for the proposed sale of securities. The filer intends to sell 4,000 shares of Common stock through UBS Financial Services Inc. (11 Madison Ave, New York) with an aggregate market value of $180,000. The approximate date of sale is 09/26/2025 on NASDAQ. The shares were acquired as Founder Shares from the issuer on 07/31/2011, and full payment was recorded on that date. The filing reports nothing to report for securities sold during the past three months. Other standard notice fields (such as a signed date of notice) are present as headers but no explicit signature date or contact details are provided in the text supplied.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice for a small proposed sale by a founder, properly routed through a broker.

The filing documents a proposed block sale of 4,000 common shares via UBS with an indicated aggregate value of $180,000 and an expected execution on 09/26/2025. The shares were acquired as founder shares on 07/31/2011 from the issuer. The notice includes the Rule 144 representation regarding material nonpublic information and indicates no reportable sales in the prior three months. From a compliance standpoint, this submission contains the core items required by Rule 144: class, broker, amount, acquisition details, and the representation about material information.

Equity Capital Markets Analyst

TL;DR: Transaction size is immaterial relative to outstanding shares; unlikely to move market or signal major insider activity.

The proposed sale of 4,000 shares against 94,175,994 shares outstanding represents a de minimis fraction of the float. The filing shows the shares are founder shares acquired in 2011 and sold through a major brokerage, consistent with routine liquidity by insiders. There is no disclosure here of other concurrent sales or a trading plan, and the filing reports no sales in the past three months. As presented, the notice appears informational and not material to valuation or market dynamics.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Ave 4th Floor New York NY 10010	4000	180000.00	94175994	09/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/31/2011	Founder Shares	Issuer			4000	07/31/2011	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for CRNX report?

The Form 144 reports a proposed sale of 4,000 common shares of Crinetics Pharmaceuticals (CRNX) through UBS Financial Services with an aggregate market value of $180,000 and an approximate sale date of 09/26/2025.

When were the shares to be sold originally acquired?

The shares were acquired as Founder Shares from the issuer on 07/31/2011.

Does the filing report other sales in the past three months?

No. The filing explicitly states Nothing to Report for securities sold during the past three months.

On which exchange is the sale expected to occur?

The filing specifies the sale is expected to occur on NASDAQ.

Who is the broker handling the proposed sale?

The broker named in the filing is UBS Financial Services Inc. at the address shown.